These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 22551459)

  • 1. HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: which sample should be used?
    Perrone G; Amato M; Callea M; Rabitti C; Righi D; Crucitti P; Coppola R; Onetti Muda A
    Histopathology; 2012 Jul; 61(1):134-5. PubMed ID: 22551459
    [No Abstract]   [Full Text] [Related]  

  • 2. Isolated CNS relapse in human epidermal growth factor receptor 2-positive esophagogastric cancer: effective treatment with trastuzumab after failure of surgery and radiotherapy.
    Geldart T; Astras G
    J Clin Oncol; 2011 Aug; 29(23):e664-5. PubMed ID: 21646609
    [No Abstract]   [Full Text] [Related]  

  • 3. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
    Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
    Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment.
    Maresch J; Schoppmann SF; Thallinger CM; Zielinski CC; Hejna M
    Crit Rev Oncol Hematol; 2012 Jun; 82(3):310-22. PubMed ID: 21783379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
    Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
    Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?
    Kumarasinghe MP; de Boer WB; Khor TS; Ooi EM; Jene N; Jayasinghe S; Fox SB
    Pathology; 2014 Apr; 46(3):184-7. PubMed ID: 24614718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted HER2 treatment in advanced gastric cancer.
    Jørgensen JT
    Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
    Hechtman JF; Polydorides AD
    Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
    Lorenzen S; Lordick F
    Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis.
    Negri FV; Bozzetti C; Ardizzoni A; Lagrasta C; Crafa P; Silini EM
    Hum Pathol; 2011 Jun; 42(6):909-10; author reply 910-1. PubMed ID: 21571126
    [No Abstract]   [Full Text] [Related]  

  • 11. Analysis of HER2 expression and gene amplification in adenocarcinoma of the stomach and the gastro-oesophageal junction: rationale for the Belgian way of working.
    Jouret-Mourin A; Hoorens A; De Hertogh G; Vanderveken J; Demetter P; Van Cutsem E
    Acta Gastroenterol Belg; 2012 Mar; 75(1):9-13. PubMed ID: 22567741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
    Kaur A; Dasanu CA
    Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2 overexpression and targeted treatment by trastuzumab in a very old patient with gastric cancer.
    Inui T; Asakawa A; Morita Y; Mizuno S; Natori T; Kawaguchi A; Murakami M; Hishikawa Y; Inui A
    J Intern Med; 2006 Nov; 260(5):484-7. PubMed ID: 17040255
    [No Abstract]   [Full Text] [Related]  

  • 14. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
    Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
    Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 testing in gastric cancer.
    Albarello L; Pecciarini L; Doglioni C
    Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
    Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
    Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
    Treacy AD; Karamchandani JR; Streutker CJ; Grin A
    Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on Gastroesophageal Adenocarcinoma Targeted Therapies.
    Maron SB; Catenacci DVT
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):511-527. PubMed ID: 28501091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 testing in gastric cancer: a practical approach.
    Rüschoff J; Hanna W; Bilous M; Hofmann M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
    Mod Pathol; 2012 May; 25(5):637-50. PubMed ID: 22222640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.
    Birkman EM; Ålgars A; Lintunen M; Ristamäki R; Sundström J; Carpén O
    BMC Cancer; 2016 Jul; 16():406. PubMed ID: 27387915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.